References
- de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML RAR alpha fusion in RNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675–684
- Kakizuka A, Miller WH, Umesono K, et al. Chromosomal translocation t(15;17) in human promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor PML. Cell 1991; 66: 663–674
- Kane JR, Head DR, Balaze L, et al. Molecular analysis of the PML/RARα chimeric gene in pediatric acute promyelocytic leukemia. Leukemia 1996; 10: 1296–1301
- Fenaux P, Pollet JP, van den Bossche L, et al. Treatment of acute promyelocytic leukemia. A report of 70 cases. Leuk Lymphoma. 1991; 2: 249–256
- Huang M, Yu Chen Y, Shu Rong C, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988; 72: 567–576
- Castaigne S, Chomienne C, Daniel MT, Berger R, Fenaux P, Degos L. All-trans retinoic acid: a differentiating therapy for acute promyelocytic leukemia. 1. Clinical results. Blood. 1990; 76: 1704–1709
- Degos L, Dombret H, Chomienne C, et al. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood. 1995; 85: 2643–2653
- Degos L. Differentiative therapy of leukemia. Leuk Lymph. 1994; 13: 39–43, suppl 1
- Fenaux P, Castaigne S, Chomienne C, Dombret H, Degos L. All-trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 1992; 6: 64–72
- Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell C. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med. 1992; 17: 292–296
- Fenaux P, Wattel E, Archimbaud E, et al. Prolonged follow up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. Blood. 1994; 84: 666–667
- Warrel RP, Maslak P, Eardley A, Heller G, Miller WH, Frankel SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid. An update of the New York experience. Leukemia 1994; 8: 926–933
- Mahmoud HH, Hurwitz CA, Roberts WM, Santana VM, Ribeiro RC, Krance RA. Tretinoin toxicity in children with acute promyelocytic leukemia. Lancet 1993; 342: 1394–1395
- Wang ZY, Sun GL, Lu JX, Gu ZJ, Huang ME, Chen SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China. Nouv Rev Fr Hematol. 1990; 32: 34–36
- Warrel RP, Frankel ST, Miller WA, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-tarns retinoic acid). N Engl J Med. 1991; 324: 1385–1392
- Fenaux P, Chomienne C, Degos L. Acute promyelocytic leukemia: biology and treatment. Semin Oncol. 1997; 24: 92–102
- Sun G, Ouyang R, Chen S, et al. Follow up of 481 patients with APL after CR using ATRA. Chin J Hematol. 1994; 15: 411–413
- Diverio D, Pandolfi PP, Rossi V, Biondi A, Pelicci PG, Lococo F. Monitoring the treatment outcome in acute promyelocytic leukemia by RT PCR. Leukemia 1994; 8: 1105–1107
- Laczika K, Mitter Bauer G, Korning L, et al. Rapid achievement of PML-RAR polymerase chain reaction negativity by combined treatment with all-trans retinoic acid and chemotherapy in acute promyelocytic leukemia. A pilot study. Leukemia 1994; 8: 1–9
- Shen ZX, Chen XS, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of APL. Remission induction in relapse and pharmakocinetics. Blood. 1996; 88: 1158, suppl 1:abst.
- Chen GQ, Zu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. As2O3 induces NB4 cell apoptosis with down regulation of Bcl-2 expression and modulation of PLM-RARα/PML proteins. Blood. 1996; 88: 1052–1061